| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab155823-10μl (Trial Size) Apply for free trial size（?） Every year, as a valued customer, you have the exclusive opportunity to explore and enjoy three different trial products of your choice, absolutely free! | 10μl | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $66.90 | |
| Ab155823-50μl | 50μl | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $201.90 | |
| Ab155823-100μl | 100μl | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $300.90 | |
| Ab155823-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,500.90 |
mAb (2F1); Mouse anti Human beta tubulin Antibody; WB, Flow, ICC / IF, ELISA; Unconjugated
| Product Name | beta Tubulin Mouse mAb - Primary antibody, for WB,Flow,ELISA,ICC/IF various applications, from Human, generated in Mouse, specific to beta tubulin, IgG3 |
|---|---|
| Synonyms | Tubulin beta-5 chain |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Azide Free, High performance, 0.8mg/mL |
| Host Species | Mouse |
| Host species | Mouse |
| Specificity | beta tubulin |
| Application | WB,Flow,ELISA,ICC/IF |
| Immunogen | Recombinant human beta tubulin |
| Positive Control | WB: HeLa, A431, HEK293, MCF7, NIH3T3 and C6 whole cell lysates Flow: HeLa cells ICC/IF: HeLa cells |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, High Performance, Validated |
| Note | 20μl卖完停产，不再备货 |
| Product Description |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Monoclonal antibodies |
| Isotype | IgG3 |
| Light Chain Type | kappa |
| SDS-PAGE | 150 kDa |
| Purification Method | Protein A purified |
| Source | Hybridoma supernatant |
| Form | Liquid |
| Concentration | 0.8mg/mL |
| Storage Temp | Store at -20°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at 4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
beta Tubulin Mouse mAb (Ab155823) - Western Blot
All lanes: beta Tubulin Mouse mAb (Ab155823) at 1/10000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Mouse IgG H&L (HRP) at 1/10000 dilution
Predicted band size: 49 kDa
Observed band size: 50 kDa
beta Tubulin Mouse mAb (Ab155823) - ICC/IF
IF analysis of beta Tubulin (green) in HeLa cells. The cells were fixed and permeabilized with 100% methanol for 5 minutes, and blocked with 2% BSA for 1 hour at room temperature. Cells were stained with beta Tubulin Mouse mAb (Ab155823) at 1/2000 dilution in blocking buffer overnight at 4°C, and then incubated with Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) at a dilution of 1/1000 for 1 hour at room temperature in the dark (green). Cells were counterstained with DAPI (blue). Images were taken on the confocal laser scanning microscope.
beta Tubulin Mouse mAb (Ab155823) - Flow Cytometry
Flow analysis of beta Tubulin (red line) in HeLa cells. The cells were fixed and permeabilized with 100% methanol for 5 minutes. Cells were stained with beta Tubulin Mouse mAb (Ab155823) at 1/2000 dilution for 1 hour at 4°C, and then incubated with Goat Anti-Mouse IgG H&L (FITC) (Ab156254) at a dilution of 1/1000 for 30 minutes at 4°C in the dark . Unlabeled sample (black line) was used as a negative control.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Application | Dilution info |
|---|---|
| IF/ICC |
0.5 μg/mL
|
| Flow Cytometry |
0.016-2.0μg/mL
|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F0800804 | Certificate of Analysis | Aug 14, 2023 | Ab155823 |
| ZJ23F0800803 | Certificate of Analysis | Aug 14, 2023 | Ab155823 |
| 1. Leandro-García LJ, Leskelä S, Landa I, Montero-Conde C, López-Jiménez E, Letón R, Cascón A, Robledo M, Rodríguez-Antona C. (2010) Tumoral and tissue-specific expression of the major human beta-tubulin isotypes.. Cytoskeleton (Hoboken), 67 (4): (214-23). [PMID:20191564] [10.1021/op500134e] |
| 2. Lu Y, Chen J, Xiao M, Li W, Miller DD. (2012) An overview of tubulin inhibitors that interact with the colchicine binding site.. Pharm Res, 29 (11): (2943-71). [PMID:22814904] [10.1021/op500134e] |
| 3. Marc Lamblin,Russell Spingarn,Tian-Tian Wang,Melanie C Burger,Basel Dabbas,Nicolas Moitessier,John H White,James L Gleason. (2010-10-05) An o-aminoanilide analogue of 1α,25-dihydroxyvitamin D(3) functions as a strong vitamin D receptor antagonist.. Journal of medicinal chemistry, 53 ((20)): (7461-7465). [PMID:20883026] |
| 4. Gasparotto V, Castagliuolo I, Chiarelotto G, Pezzi V, Montanaro D, Brun P, Palù G, Viola G, Ferlin MG.. (2006) Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity.. J Med Chem, 49 (6): (1910-1915). [PMID:16539377] [10.1021/jm0510676] |
| 5. Fortin S, Moreau E, Lacroix J, Côté MF, Petitclerc E, C-Gaudreault R.. (2010) Synthesis, antiproliferative activity evaluation and structure-activity relationships of novel aromatic urea and amide analogues of N-phenyl-N'-(2-chloroethyl)ureas.. Eur J Med Chem, 45 (7): (2928-2937). [PMID:20400211] [10.1016/j.ejmech.2010.03.018] |
| 6. McNamara YM, Cloonan SM, Knox AJ, Keating JJ, Butler SG, Peters GH, Meegan MJ, Williams DC.. (2011) Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.. Bioorg Med Chem, 19 (3): (1328-1348). [PMID:21227702] [10.1016/j.bmc.2010.11.054] |
| 7. Romagnoli R, Baraldi PG, Brancale A, Ricci A, Hamel E, Bortolozzi R, Basso G, Viola G.. (2011) Convergent synthesis and biological evaluation of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents.. J Med Chem, 54 (14): (5144-5153). [PMID:21663319] [10.1021/jm200392p] |
| 8. Lai MJ, Huang HL, Pan SL, Liu YM, Peng CY, Lee HY, Yeh TK, Huang PH, Teng CM, Chen CS, Chuang HY, Liou JP.. (2012) Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.. J Med Chem, 55 (8): (3777-3791). [PMID:22439863] [10.1021/jm300197a] |
| 9. Wang XF, Ohkoshi E, Wang SB, Hamel E, Bastow KF, Morris-Natschke SL, Lee KH, Xie L.. (2013) Synthesis and biological evaluation of N-alkyl-N-(4-methoxyphenyl)pyridin-2-amines as a new class of tubulin polymerization inhibitors.. Bioorg Med Chem, 21 (3): (632-642). [PMID:23274123] [10.1016/j.bmc.2012.11.047] |
| 10. Bio M, Rajaputra P, Nkepang G, Awuah SG, Hossion AM, You Y.. (2013) Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry.. J Med Chem, 56 (10): (3936-3942). [PMID:23631389] [10.1021/jm400139w] |
| 11. Zhao Y, Su J, Goto M, Morris-Natschke SL, Li Y, Zhao QS, Yao ZJ, Lee KH.. (2013) Dual-functional abeo-taxane derivatives destabilizing microtubule equilibrium and inhibiting NF-κB activation.. J Med Chem, 56 (11): (4749-4757). [PMID:23725535] [10.1021/jm400479p] |
| 12. Wang XF, Wang SB, Ohkoshi E, Wang LT, Hamel E, Qian K, Morris-Natschke SL, Lee KH, Xie L.. (2013) N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin.. Eur J Med Chem, 67 (196-207). [PMID:23867604] [10.1016/j.ejmech.2013.06.041] |
| 13. Cheng YY, Liu CY, Tsai MT, Lin HY, Yang JS, Wu TS, Kuo SC, Huang LJ, Lee KH.. (2013) Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead.. Bioorg Med Chem Lett, 23 (18): (5223-5227). [PMID:23916255] [10.1016/j.bmcl.2013.06.083] |
| 14. Frolova LV, Magedov IV, Romero AE, Karki M, Otero I, Hayden K, Evdokimov NM, Banuls LM, Rastogi SK, Smith WR, Lu SL, Kiss R, Shuster CB, Hamel E, Betancourt T, Rogelj S, Kornienko A.. (2013) Exploring natural product chemistry and biology with multicomponent reactions. 5. Discovery of a novel tubulin-targeting scaffold derived from the rigidin family of marine alkaloids.. J Med Chem, 56 (17): (6886-6900). [PMID:23927793] [10.1021/jm400711t] |
| 15. Hadimani MB, Macdonough MT, Ghatak A, Strecker TE, Lopez R, Sriram M, Nguyen BL, Hall JJ, Kessler RJ, Shirali AR, Liu L, Garner CM, Pettit GR, Hamel E, Chaplin DJ, Mason RP, Trawick ML, Pinney KG.. (2013) Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.. J Nat Prod, 76 (9): (1668-1678). [PMID:24016002] [10.1021/np400374w] |
| 16. Macdonough MT, Strecker TE, Hamel E, Hall JJ, Chaplin DJ, Trawick ML, Pinney KG.. (2013) Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (OXi8006).. Bioorg Med Chem, 21 (21): (6831-6843). [PMID:23993969] [10.1016/j.bmc.2013.07.028] |
| 17. Sang CY, Xu XH, Qin WW, Liu JF, Hui L, Chen SW.. (2013) DPMA, a deoxypodophyllotoxin derivative, induces apoptosis and anti-angiogenesis in non-small cell lung cancer A549 cells.. Bioorg Med Chem Lett, 23 (24): (6650-6655). [PMID:24231363] [10.1016/j.bmcl.2013.10.048] |
| 18. Romagnoli R, Baraldi PG, Lopez-Cara C, Preti D, Aghazadeh Tabrizi M, Balzarini J, Bassetto M, Brancale A, Fu XH, Gao Y, Li J, Zhang SZ, Hamel E, Bortolozzi R, Basso G, Viola G.. (2013) Concise synthesis and biological evaluation of 2-Aroyl-5-amino benzo[b]thiophene derivatives as a novel class of potent antimitotic agents.. J Med Chem, 56 (22): (9296-9309). [PMID:24164557] [10.1021/jm4013938] |
| 19. Wang XF, Guan F, Ohkoshi E, Guo W, Wang L, Zhu DQ, Wang SB, Wang LT, Hamel E, Yang D, Li L, Qian K, Morris-Natschke SL, Yuan S, Lee KH, Xie L.. (2014) Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.. J Med Chem, 57 (4): (1390-1402). [PMID:24502232] [10.1021/jm4016526] |
| 20. Tanpure RP, George CS, Sriram M, Strecker TE, Tidmore JK, Hamel E, Charlton-Sevcik AK, Chaplin DJ, Trawick ML, Pinney KG.. (2012) An Amino-Benzosuberene Analogue That Inhibits Tubulin Assembly and Demonstrates Remarkable Cytotoxicity.. Medchemcomm, 3 (6): (720-724). [PMID:23772309] [10.1039/c2md00318j] |
| 21. Penthala NR, Sonar VN, Horn J, Leggas M, Yadlapalli JS, Crooks PA.. (2013) Synthesis and evaluation of a series of benzothiophene acrylonitrile analogs as anticancer agents.. Medchemcomm, 4 (7): (1073-1078). [PMID:23956835] [10.1039/c3md00130j] |
| 22. Zheng S, Zhong Q, Mottamal M, Zhang Q, Zhang C, Lemelle E, McFerrin H, Wang G.. (2014) Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents.. J Med Chem, 57 (8): (3369-3381). [PMID:24669888] [10.1021/jm500002k] |
| 23. Romagnoli R, Baraldi PG, Salvador MK, Chayah M, Camacho ME, Prencipe F, Hamel E, Consolaro F, Basso G, Viola G.. (2014) Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents.. Eur J Med Chem, 81 (394-407). [PMID:24858544] [10.1016/j.ejmech.2014.05.028] |
| 24. Krasavin M, Sosnov AV, Karapetian R, Konstantinov I, Soldatkina O, Godovykh E, Zubkov F, Bai R, Hamel E, Gakh AA.. (2014) Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype.. Bioorg Med Chem Lett, 24 (18): (4477-4481). [PMID:25155551] [10.1016/j.bmcl.2014.07.089] |
| 25. Kamal A, Shaik B, Nayak VL, Nagaraju B, Kapure JS, Shaheer Malik M, Shaik TB, Prasad B.. (2014) Synthesis and biological evaluation of 1,2,3-triazole linked aminocombretastatin conjugates as mitochondrial mediated apoptosis inducers.. Bioorg Med Chem, 22 (19): (5155-5167). [PMID:25192811] [10.1016/j.bmc.2014.08.008] |
| 26. Shareef MA, Duscharla D, Ramasatyaveni G, Dhoke NR, Das A, Ummanni R, Srivastava AK.. (2015) Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties.. Eur J Med Chem, 89 (128-137). [PMID:25462233] [10.1016/j.ejmech.2014.10.050] |
| 27. Romagnoli R, Baraldi PG, Salvador MK, Prencipe F, Bertolasi V, Cancellieri M, Brancale A, Hamel E, Castagliuolo I, Consolaro F, Porcù E, Basso G, Viola G.. (2014) Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles.. J Med Chem, 57 (15): (6795-6808). [PMID:25025853] [10.1021/jm5008193] |
| 28. La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Sisinni L, Bolognesi A, Rensen WM, Miele A, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Brancale A, Novellino E, Dondio G, Vultaggio S, Varasi M, Mercurio C, Hamel E, Lavia P, Silvestri R.. (2014) New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.. J Med Chem, 57 (15): (6531-6552). [PMID:25025991] [10.1021/jm500561a] |
| 29. Penthala NR, Zong H, Ketkar A, Madadi NR, Janganati V, Eoff RL, Guzman ML, Crooks PA.. (2015) Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents.. Eur J Med Chem, 92 (212-220). [PMID:25557492] [10.1016/j.ejmech.2014.12.050] |
| 30. Ramanivas T, Sushma B, Nayak VL, Chandra Shekar K, Srivastava AK.. (2015) Design, synthesis and biological evaluations of chirally pure 1,2,3,4-tertrahydroisoquinoline analogs as anti-cancer agents.. Eur J Med Chem, 92 (608-618). [PMID:25615796] [10.1016/j.ejmech.2015.01.030] |
| 31. Trabbic CJ, Overmeyer JH, Alexander EM, Crissman EJ, Kvale HM, Smith MA, Erhardt PW, Maltese WA.. (2015) Synthesis and biological evaluation of indolyl-pyridinyl-propenones having either methuosis or microtubule disruption activity.. J Med Chem, 58 (5): (2489-2512). [PMID:25654321] [10.1021/jm501997q] |
| 32. La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Verrico A, Miele A, Monti L, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Ricci B, Soriani A, Santoni A, Caraglia M, Porto S, Da Pozzo E, Martini C, Brancale A, Marinelli L, Novellino E, Vultaggio S, Varasi M, Mercurio C, Bigogno C, Dondio G, Hamel E, Lavia P, Silvestri R.. (2015) New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer.. J Med Chem, 58 (15): (5789-5807). [PMID:26132075] [10.1021/acs.jmedchem.5b00310] |
| 33. Wang SB, Wang XF, Qin B, Ohkoshi E, Hsieh KY, Hamel E, Cui MT, Zhu DQ, Goto M, Morris-Natschke SL, Lee KH, Xie L.. (2015) Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors.. Bioorg Med Chem, 23 (17): (5740-5747). [PMID:26242242] [10.1016/j.bmc.2015.07.016] |
| 34. Raffa D, Maggio B, Plescia F, Cascioferro S, Raimondi MV, Cancemi G, D'Anneo A, Lauricella M, Cusimano MG, Bai R, Hamel E, Daidone G.. (2015) Synthesis, antiproliferative activity and possible mechanism of action of novel 2-acetamidobenzamides bearing the 2-phenoxy functionality.. Bioorg Med Chem, 23 (19): (6305-6316). [PMID:26344588] [10.1016/j.bmc.2015.08.027] |
| 35. Medellin DC, Zhou Q, Scott R, Hill RM, Frail SK, Dasari R, Ontiveros SJ, Pelly SC, van Otterlo WA, Betancourt T, Shuster CB, Hamel E, Bai R, LaBarbera DV, Rogelj S, Frolova LV, Kornienko A.. (2016) Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities.. J Med Chem, 59 (1): (480-485). [PMID:26641132] [10.1021/acs.jmedchem.5b01426] |
| 36. Madadi NR, Ketkar A, Penthala NR, Bostian AC, Eoff RL, Crooks PA.. (2016) Dioxol and dihydrodioxin analogs of 2- and 3-phenylacetonitriles as potent anti-cancer agents with nanomolar activity against a variety of human cancer cells.. Bioorg Med Chem Lett, 26 (9): (2164-2169). [PMID:27017113] [10.1016/j.bmcl.2016.03.068] |
| 37. Dalal K, Morin H, Ban F, Shepherd A, Fernandez M, Tam KJ, Li H, LeBlanc E, Lack N, Prinz H, Rennie PS, Cherkasov A.. (2018) Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.. Eur J Med Chem, 157 (1164-1173). [PMID:30193215] [10.1016/j.ejmech.2018.08.059] |
| 38. Pavana RK, Shah K, Gentile T, Dybdal-Hargreaves NF, Risinger AL, Mooberry SL, Hamel E, Gangjee A.. (2018) Sterically induced conformational restriction: Discovery and preclinical evaluation of novel pyrrolo[3,2-d]pyrimidines as microtubule targeting agents.. Bioorg Med Chem, 26 (20): (5470-5478). [PMID:30297118] [10.1016/j.bmc.2018.09.025] |
| 39. Puxeddu M, Shen H, Bai R, Coluccia A, Nalli M, Mazzoccoli C, Da Pozzo E, Cavallini C, Martini C, Orlando V, Biagioni S, Mazzoni C, Coluccia AML, Hamel E, Liu T, Silvestri R, La Regina G.. (2020) Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies.. Eur J Med Chem, 185 (111828-111828). [PMID:31727471] [10.1016/j.ejmech.2019.111828] |
| 40. Wan Y, Li Y, Yan C, Yan M, Tang Z.. (2019) Indole: A privileged scaffold for the design of anti-cancer agents.. Eur J Med Chem, 183 (111691-111691). [PMID:31536895] [10.1016/j.ejmech.2019.111691] |
| 41. Bommagani S, Penthala NR, Balasubramaniam M, Kuravi S, Caldas-Lopes E, Guzman ML, Balusu R, Crooks PA.. (2019) A novel tetrazole analogue of resveratrol is a potent anticancer agent.. Bioorg Med Chem Lett, 29 (2): (172-178). [PMID:30528695] [10.1016/j.bmcl.2018.12.006] |
| 42. Du L, Risinger AL, Yee SS, Ola ARB, Zammiello CL, Cichewicz RH, Mooberry SL.. (2019) Identification of C-6 as a New Site for Linker Conjugation to the Taccalonolide Microtubule Stabilizers.. J Nat Prod, 82 (3): (583-588). [PMID:30799622] [10.1021/acs.jnatprod.8b01036] |
| 43. Devambatla RK, Namjoshi OA, Choudhary S, Hamel E, Shaffer CV, Rohena CC, Mooberry SL, Gangjee A.. (2016) Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells.. J Med Chem, 59 (12): (5752-5765). [PMID:27213719] [10.1021/acs.jmedchem.6b00237] |
| 44. Winn BA, Devkota L, Kuch B, MacDonough MT, Strecker TE, Wang Y, Shi Z, Gerberich JL, Mondal D, Ramirez AJ, Hamel E, Chaplin DJ, Davis P, Mason RP, Trawick ML, Pinney KG.. (2020) Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.. J Nat Prod, 83 (4): (937-954). [PMID:32196334] [10.1021/acs.jnatprod.9b00773] |
| 45. Patel OPS,Arun A,Singh PK,Saini D,Karade SS,Chourasia MK,Konwar R,Yadav PP. (2019) Pyranocarbazole derivatives as potent anti-cancer agents triggering tubulin polymerization stabilization induced activation of caspase-dependent apoptosis and downregulation of Akt/mTOR in breast cancer cells.. Eur J Med Chem, 167 (226-244). [PMID:30772606] [10.1016/j.ejmech.2019.02.003] |
| 46. Hengst JA,Hegde S,Paulson RF,Yun JK. (2020) Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization.. Bioorg Med Chem Lett, 30 (20.0): (127453-127453). [PMID:32736077] [10.1016/j.bmcl.2020.127453] |
| 47. Malebari AM,Fayne D,Nathwani SM,O'Connell F,Noorani S,Twamley B,O'Boyle NM,O'Sullivan J,Zisterer DM,Meegan MJ. (2020) β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells.. Eur J Med Chem, 189 (112050-112050). [PMID:31954879] [10.1016/j.ejmech.2020.112050] |
| 48. Malik HS,Bilal A,Ullah R,Iqbal M,Khan S,Ahmed I,Krohn K,Saleem RSZ,Hussain H,Faisal A. (2020) Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors.. J Nat Prod, 83 (10): (3111-3121). [PMID:32975953] [10.1021/acs.jnatprod.0c00699] |
| 49. Ma W,Chen P,Huo X,Ma Y,Li Y,Diao P,Yang F,Zheng S,Hu M,You W,Zhao P. (2020) Development of triazolothiadiazine derivatives as highly potent tubulin polymerization inhibitors: Structure-activity relationship, in vitro and in vivo study.. Eur J Med Chem, 208 (112847-112847). [PMID:33022479] [10.1016/j.ejmech.2020.112847] |
| 50. Tantak MP,Malik M,Klingler L,Olson Z,Kumar A,Sadana R,Kumar D. (2021) Indolyl-α-keto-1,3,4-oxadiazoles: Synthesis, anti-cell proliferation activity, and inhibition of tubulin polymerization.. Bioorg Med Chem Lett, 37 (127842-127842). [PMID:33556575] [10.1016/j.bmcl.2021.127842] |
| 51. Singh A,Chang TY,Kaur N,Hsu KC,Yen Y,Lin TE,Lai MJ,Lee SB,Liou JP. (2021) CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.. Eur J Med Chem, 215 (113169-113169). [PMID:33588178] [10.1016/j.ejmech.2021.113169] |
| 52. Lee, M G MG, Lewis, S A SA, Wilde, C D CD and Cowan, N J NJ.. (1983) Evolutionary history of a multigene family: an expressed human beta-tubulin gene and three processed pseudogenes.. Cell, [PMID:6688039] |
| 53. Hall, J L JL, Dudley, L L, Dobner, P R PR, Lewis, S A SA and Cowan, N J NJ.. (1983) Identification of two human beta-tubulin isotypes.. Molecular and cellular biology, [PMID:6865944] |
| 54. Crabtree, D V DV, Ojima, I I, Geng, X X and Adler, A J AJ.. (2001) Tubulins in the primate retina: evidence that xanthophylls may be endogenous ligands for the paclitaxel-binding site.. Bioorganic & medicinal chemistry, [PMID:11504633] |
| 55. Yee, Karen W L KW and 19 more authors.. (2005) Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.. Clinical cancer research : an official journal of the American Association for Cancer Research, (15): [PMID:16166440] |
| 56. Fourest-Lieuvin, Anne A and 6 more authors.. (2006) Microtubule regulation in mitosis: tubulin phosphorylation by the cyclin-dependent kinase Cdk1.. Molecular biology of the cell, [PMID:16371510] |
| 57. Kurtzberg, Leslie S LS and 8 more authors.. (2009) Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.. Cancer chemotherapy and pharmacology, [PMID:19277662] |
| 58. Rogowski, Krzysztof K and 10 more authors.. (2009) Evolutionary divergence of enzymatic mechanisms for posttranslational polyglycylation.. Cell, (12): [PMID:19524510] |
| 59. Sève, P P and Dumontet, C C.. (2010) [Class III beta tubulin expression in nonsmall cell lung cancer].. Revue des maladies respiratoires, [PMID:20403547] |
| 60. Finkelstein, Yaron Y and 8 more authors.. (2010) Colchicine poisoning: the dark side of an ancient drug.. Clinical toxicology (Philadelphia, Pa.), [PMID:20586571] |
| 61. Kinzel, Doris D and 10 more authors.. (2010) Pitchfork regulates primary cilia disassembly and left-right asymmetry.. Developmental cell, (20): [PMID:20643351] |
| 62. Anbalagan, Muralidharan M and 8 more authors.. (2012) Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.. Molecular cancer therapeutics, [PMID:22784709] |
| 63. Breuss, Martin M and 22 more authors.. (2012) Mutations in the β-tubulin gene TUBB5 cause microcephaly with structural brain abnormalities.. Cell reports, (27): [PMID:23246003] |
| 64. Li, Donghui D, Dammer, Eric B EB, Lucki, Natasha C NC and Sewer, Marion B MB.. (2013) cAMP-stimulated phosphorylation of diaphanous 1 regulates protein stability and interaction with binding partners in adrenocortical cells.. Molecular biology of the cell, [PMID:23325789] |
| 65. Isrie, Mala M and 23 more authors.. (2015) Mutations in Either TUBB or MAPRE2 Cause Circumferential Skin Creases Kunze Type.. American journal of human genetics, (3): [PMID:26637975] |
| 66. Valenstein, Max L ML and Roll-Mecak, Antonina A.. (2016) Graded Control of Microtubule Severing by Tubulin Glutamylation.. Cell, (25): [PMID:26875866] |
| 67. Waight, Andrew B and 5 more authors.. (2016) Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics.. PloS one, [PMID:27518442] |
| 68. Niu, Lu and 7 more authors.. (2019) Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity.. The Journal of biological chemistry, (29): [PMID:31628188] |
